GCP
ARQT icon

GSA Capital Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

GSA Capital Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$860K Sell
32,797
-13,290
-29% -$310K 0.05% 609
2026
Q1 		$1.09M Buy
46,087
+33,962
+280% +$867K 0.07% 447
2025
Q4 		$352K Sell
12,125
-21,567
-64% -$552K 0.03% 1076
2025
Q3 		$635K Buy
33,692
+18,017
+115% +$284K 0.05% 685
2025
Q2 		$220K Sell
15,675
-6,231
-28% -$87.4K 0.02% 1460
2025
Q1 		$343K Buy
+21,906
New +$309K 0.03% 1052
2024
Q4 		– Sell
-237,174
Closed -$2.21M – 1590
2024
Q3 		$2.21M Buy
237,174
+208,599
+730% +$2.06M 0.17% 97
2024
Q2 		$266K Sell
28,575
-7,973
-22% -$72.1K 0.02% 1330
2024
Q1 		$362K Sell
36,548
-38,306
-51% -$286K 0.03% 1096
2023
Q4 		$242K Buy
+74,854
New +$203K 0.02% 1225
2022
Q2 		– Sell
-27,851
Closed -$536K – 1383
2022
Q1 		$536K Buy
+27,851
New +$471K 0.07% 478

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GSA Capital Partners's ARQT Position: Q2 2026 in Review

GSA Capital Partners reduced its Arcutis Biotherapeutics (ARQT) stake by 29% in Q2 2026, selling an estimated $310K and leaving 32,797 shares worth $860K. The position accounts for 0.05% of the portfolio, ranked #609.

GSA Capital Partners first reported a position in ARQT in Q1 2022 and has held it in 11 quarters since. The position peaked at $2.21M in Q3 2024. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • GSA Capital Partners held 32,797 shares of Arcutis Biotherapeutics worth $860K as of Q2 2026.
  • GSA Capital Partners sold 13,290 Arcutis Biotherapeutics shares in Q2 2026, an estimated $310K.
  • Arcutis Biotherapeutics made up 0.05% of GSA Capital Partners's portfolio in Q2 2026, its #609 holding.
  • GSA Capital Partners first reported a position in Arcutis Biotherapeutics in Q1 2022 and has held it in 11 quarters since.
  • GSA Capital Partners's Arcutis Biotherapeutics position peaked at $2.21M in Q3 2024.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.